Abstract
Purpose: Evaluate the effect of Montelukast as a potencial drug to be used in the treatment of ulcerative colitis. Methods: We evaluated the effect of Montelukast (MK), a selective antagonist of the LTD4 receptor, at different doses (1, 5 and 10 mg/kg), in the setting of acute experimentally rectocolitis model induced through the acetic acid method in Sprague Dowley rats. Each experimental group was composed of six rats (n: 6), macroscopic and microscopic evaluation of the severity of inflammation, hemorrhage and necrosis was performed and weight trend was documented over seven days. Results: MK produced either a significant or total reduction of inflammation, hemorrhage and necrosis induced by the acetic acid (p<0.05). In contrast with the control group or low dose group, rats treated with intermediate or high doses of MK developed only minimal weight loss for the first two days with recovery of pre treatment weight after the third day of therapy. Conclusion: Results of this study suggest that MK could be a potentially helpful drug in the treatment of acute ulcerative rectocolitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
